help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fox, E.
Right arrow Articles by Balis, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fox, E.
Right arrow Articles by Balis, F. M.
The Oncologist, Vol. 7, No. 5, 401–409, October 2002
© 2002 AlphaMed Press

Clinical Trial Design for Target-Based Therapy

Elizabeth Fox, Gregory A. Curt, Frank M. Balis

Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA

Correspondence: Elizabeth Fox, M.D., Pediatric Oncology Branch, CCR, NCI, Building 10/Room 13C103, 10 Center Drive, MSC 1920, Bethesda, Maryland 20892-1920, USA. Telephone: 301-402-6641; Fax: 301-480-8871; e-mail: foxb{at}mail.nih.gov

Anticancer drug discovery has shifted from an empiric random screening directed approach to a more rational and mechanistic, target-based approach, which reflects our rapidly expanding knowledge of the pathogenesis of a variety of forms of cancer at the molecular level, providing new targets for drug discovery and development. The clinical development of target-based anticancer drugs will require fundamental changes to the traditional clinical trial design and end points that have been used for conventional cytotoxic drugs. In the phase I and II settings, traditional end points (toxicity and response) may not be suitable for more selective, cytostatic target-based agents, and these end points may be replaced by biological or pharmacokinetic end points to define the optimal doses and the therapeutic effects of these drugs on their targets. For phase III trials, measurable clinical benefit will continue to be the primary end point. As our understanding of the complex pathways and networks controlling cell signaling, proliferation, and cell death expands, we must learn how and when to use agents to target specific steps in malignant transformation and proliferation, and we must adapt clinical trial design to test the clinical utility of this promising new class of anticancer drugs.

Key Words. Clinical trials • Drug development • Pharmacokinetics • Pharmacodynamics • Molecular targets




This article has been cited by other articles:


Home page
 JCOHome page
P. Fu, A. Dowlati, and M. Schluchter
Comparison of Power Between Randomized Discontinuation Design and Upfront Randomization Design on Progression-Free Survival
J. Clin. Oncol., September 1, 2009; 27(25): 4135 - 4141.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
S. M. Chang, K. R. Lamborn, J. G. Kuhn, W.K. A. Yung, M. R. Gilbert, P. Y. Wen, H. A. Fine, M. P. Mehta, L. M. DeAngelis, F. S. Lieberman, et al.
Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium
Neuro-oncol, August 1, 2008; 10(4): 631 - 642.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Kim, E. Fox, K. Warren, S. M. Blaney, S. L. Berg, P. C. Adamson, M. Libucha, E. Byrley, F. M. Balis, and B. C. Widemann
Characteristics and Outcome of Pediatric Patients Enrolled in Phase I Oncology Trials
Oncologist, June 1, 2008; 13(6): 679 - 689.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. R. Tseng, K. W. Kang, M. Dandekar, S. Yaghoubi, J. H. Lee, J. G. Christensen, S. Muir, P. W. Vincent, N. R. Michaud, and S. S. Gambhir
Preclinical Efficacy of the c-Met Inhibitor CE-355621 in a U87 MG Mouse Xenograft Model Evaluated by 18F-FDG Small-Animal PET
J. Nucl. Med., January 1, 2008; 49(1): 129 - 134.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Agulnik, A. M. Oza, G. R. Pond, and L. L. Siu
Impact and Perceptions of Mandatory Tumor Biopsies for Correlative Studies in Clinical Trials of Novel Anticancer Agents
J. Clin. Oncol., October 20, 2006; 24(30): 4801 - 4807.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S.-J. Cozzi, P. G. Parsons, S. M. Ogbourne, J. Pedley, and G. M. Boyle
Induction of Senescence in Diterpene Ester-Treated Melanoma Cells via Protein Kinase C-Dependent Hyperactivation of the Mitogen-Activated Protein Kinase Pathway.
Cancer Res., October 15, 2006; 66(20): 10083 - 10091.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. A. Carducci and A. Jimeno
Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
Clin. Cancer Res., October 15, 2006; 12(20): 6296s - 6300s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. J. Vickers, J. Kuo, and B. R. Cassileth
Unconventional Anticancer Agents: A Systematic Review of Clinical Trials
J. Clin. Oncol., January 1, 2006; 24(1): 136 - 140.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Freidlin and R. Simon
Evaluation of Randomized Discontinuation Design
J. Clin. Oncol., August 1, 2005; 23(22): 5094 - 5098.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Gasparini, R. Longo, M. Fanelli, and B. A. Teicher
Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions
J. Clin. Oncol., February 20, 2005; 23(6): 1295 - 1311.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. D. Anderson, P. C. Adamson, S. L. Weiner, M. S. McCabe, and M. A. Smith
Tissue Collection for Correlative Studies in Childhood Cancer Clinical Trials: Ethical Considerations and Special Imperatives
J. Clin. Oncol., December 1, 2004; 22(23): 4846 - 4850.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
T. G. Roberts Jr, B. H. Goulart, L. Squitieri, S. C. Stallings, E. F. Halpern, B. A. Chabner, G. S. Gazelle, S. N. Finkelstein, and J. W. Clark
Trends in the Risks and Benefits to Patients With Cancer Participating in Phase 1 Clinical Trials
JAMA, November 3, 2004; 292(17): 2130 - 2140.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Simon and A. Maitournam
Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials
Clin. Cancer Res., October 15, 2004; 10(20): 6759 - 6763.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Wolf, H. Swaisland, and S. Averbuch
Development of the Novel Biologically Targeted Anticancer Agent Gefitinib: Determining the Optimum Dose for Clinical Efficacy
Clin. Cancer Res., July 15, 2004; 10(14): 4607 - 4613.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
R. K. Benjamin, F. H. Hochberg, E. Fox, P. M. Bungay, W. F. Elmquist, C. F. Stewart, J. M. Gallo, J. M. Collins, R. P. Pelletier, J. F. de Groot, et al.
Review of microdialysis in brain tumors, from concept to application: First Annual Carolyn Frye-Halloran Symposium
Neuro-oncol, January 1, 2004; 6(1): 65 - 74.
[Abstract] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. N. Gardner and M. Fernandes
New tools for cancer chemotherapy: computational assistance for tailoring treatments
Mol. Cancer Ther., October 1, 2003; 2(10): 1079 - 1084.
[Abstract] [Full Text]

Home page
 BloodHome page
L. Catley, E. Weisberg, Y.-T. Tai, P. Atadja, S. Remiszewski, T. Hideshima, N. Mitsiades, R. Shringarpure, R. LeBlanc, D. Chauhan, et al.
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma
Blood, October 1, 2003; 102(7): 2615 - 2622.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2002 by AlphaMed Press.